15 January 2021 (Friday) - ASH update

The nice people at the American Society of Hematology sent an update today. They send a lot of them, and most seem to focus on money, but this one was of more clinical interest.


Devimistat Receives FDA Fast Track Designation for AML
The FDA has cleared Rafael Pharmaceuticals to begin the phase III ARMADA 2000 trial evaluating devimistat for the treatment of acute myeloid leukemia.
Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms
Results from a CRISPR/Cas9 screening study suggest that STK11 could serve as a potential candidate tumor suppressor gene in patients with post-MPN acute myeloid leukemia.
Precision Medicine Approach Deemed Safe, Feasible for Older Patients With Untreated AML
Investigators also found that delaying treatment until mutational data were available did not seem to increase the risk of early death or adversely affect overall survival.

No comments:

Post a Comment